6127-11-3

Usage

Uses

Used in Pharmaceutical Industry:
(4-BROMO-2-NITRO-PHENYL)-ACETIC ACID is used as a key intermediate compound for the synthesis of GNF-5837 derivatives. These derivatives are selective TRK inhibitors, which have demonstrated efficacy in rodent cancer tumor models. By targeting the tropomyosin receptor kinase (TRK) family, these inhibitors can potentially play a significant role in the development of novel cancer therapies.
Used in Chemical Research:
In addition to its pharmaceutical applications, (4-BROMO-2-NITRO-PHENYL)-ACETIC ACID may also be utilized in chemical research for the development of new compounds with potential applications in various industries. Its unique structure allows for further functionalization and exploration of its properties, which could lead to the discovery of new materials or processes.

InChI:InChI=1/C8H6BrNO4/c9-6-2-1-5(3-8(11)12)7(4-6)10(13)14/h1-2,4H,3H2,(H,11,12)

Upstream product

• 60956-26-5 4-bromo-2-nitrotoluene 
• 95-92-1 oxalic acid diethyl ester 
• 100487-82-9 4-bromo-2-nitro-benzoic acid methyl ester 
• 364-73-8 4-Bromo-1-fluoro-2-nitrobenzene 
• 199328-34-2 diethyl 2-(4-bromo-2-nitrophenyl)malonate 
• 100487-81-8 2-(4-bromo-2-nitro-phenyl)malonic acid dimethyl ester 
• 119-32-4 4-Methyl-3-nitroanilin 
• 442521-40-6 ethyl 3-(4-bromo-2-nitrophenyl)-2-oxopropanoate 
• 99365-39-6 3-(4-bromo-2-nitrophenyl)-2-oxopropanoic acid 

Downstream Products

• 56988-25-1 C₁₅H₈Br₃NO₄ 
• 1190866-02-4 6’-bromospiro[cyclohexane-1,3’-indolin]-2’-one 
• 887398-81-4 C₃₂H₂₈F₃N₅O₃ 
• 1353644-07-1 1-(2-fluoro-5-(trifluoromethyl)phenyl)-3-(4-methyl-3-((2-oxoindolin-6-yl)amino)phenyl)urea 
• 887398-72-3 N-(3-((3-((1H-pyrrol-2-yl)methylene)-2-oxoindolin-6-yl)amino)phenyl)-3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)benzamide 

Relevant academic research and scientific papers

Discovery of GNF-5837, a selective TRK inhibitor with efficacy in rodent cancer tumor models

Neurotrophins and their receptors (TRKs) play key roles in the development of the nervous system and the maintenance of the neural network. Accumulating evidence points to their role in malignant transformations, chemotaxis, metastasis, and survival signaling and may contribute to the pathogenesis of a variety of tumors of both neural and non-neural origin. By screening the GNF kinase collection, a series of novel oxindole inhibitors of TRKs were identified. Optimization led to the identification of GNF-5837 (22), a potent, selective, and orally bioavailable pan-TRK inhibitor that inhibited tumor growth in a mouse xenograft model derived from RIE cells expressing both TRKA and NGF. The properties of 22 make it a good tool for the elucidation of TRK biology in cancer and other nononcology indications.

Indolin-2-one p38α inhibitors I: Design, profiling and crystallographic binding mode

The use of structure-based design and molecular modeling led to the discovery of indolin-2-one derivatives as potent and selective p38α inhibitors. The predicted binding mode was confirmed by X-ray crystallography.

New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors

This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.

New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors

This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.

Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (e.g., indazoles and benzothiazoles), which act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly di

Synthesis and biological evaluation of 3-ethylidene-1,3-dihydro-indol-2- ones as novel checkpoint 1 inhibitors

Chk1 inhibitors have emerged as a novel class of neoplastic agents for abrogating the G2 DNA damage checkpoint arrest. Analogs of the Chk1 inhibitor, 3-ethylidene-1,3-dihydro-indol-2-one, were synthesized and tested in vitro for their inhibitory activitie

INDOLES, 1H-INDAZOLES, 1,2-BENZISOXAZOLES, AND 1,2-BENZISOTHIAZOLES, AND PREPARATION AND USES THEREOF

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds for example, indoles, 1H-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, which act as ligands for the α7 nAChR subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.